特发性炎性肌病

Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York, NY: Oxford University Press USA; 2001.

Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.

• 摘要

Greenberg SA. Inflammatory myopathies: disease mechanisms. Curr Opin Neurol. 2009;22:516-523.

• 摘要

Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2 suppl 1):S57-S107.

• 摘要

Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88:83-105.

• 摘要

Ruperto N, Pistorio A, Oliveira S, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671-678.

• 摘要

1.  Karpati G, Hilton-Jones D, Griggs RC. Disorders of voluntary muscle. 7th ed. Cambridge, UK: Cambridge University Press; 2001.

2.  Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York, NY: Oxford University Press USA; 2001.

3.  Targoff IN. Polymyositis and dermatomyositis in adults. In: Maddison PJ, Isenberg DA, Woo P, et al, eds. Oxford textbook of rheumatology. 2nd ed. New York, NY: Oxford University Press USA;1988:1249-1286.

4.  Madan V, Chinoy H, Griffiths CE, et al. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol. 2009;34:451-455.

• 摘要

5.  Engel A, Franzini-Armstrong C. Myology: basic and clinical. 3rd ed. New York: McGraw-Hill, Medical Publishing Division; 2004.

6.  Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001;134:1087-1095.

• 摘要

7.  Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41:729-734.

• 摘要

8.  Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96-100.

• 摘要

9.  Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet. 2001;357:85-86.

• 摘要

10.  Scheinfeld N. A review of the cutaneous paraneoplastic associations and metastatic presentations of ovarian carcinoma. Clin Exp Dermatol. 2008;33:10-15.

• 摘要

11.  Medsger TA, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715-723.

• 摘要

12.  Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-1334.

• 摘要

13.  Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10:1-9.

• 摘要

14.  Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23:970-972.

• 摘要

15.  Health & Social Care Information Centre. Hospital Episode Statistics (HES). http://www.hesonline.nhs.uk (last accessed 4 April 2016).

• 全文

16.  Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.

• 摘要

17.  Vargas-Leguas H, Selva-O'Callaghan A, Campins-Marti M, et al. Polymyositis-dermatomyositis: incidence in Spain (1997-2004) [in Spanish]. Med Clin (Barc) 2007;129:721-724.

• 摘要

18.  Patrick M, Buchbinder R, Jolley D, et al. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of apatial clustering. J Rheumatol. 1999;26:1094-1100.

• 摘要

19.  Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000;55:1385-1387.

• 摘要

20.  Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006;66(2 suppl 1):S33-S38.

• 摘要

21.  Chou SM. Inclusion body myositis: a chronic persistent mumps myositis? Hum Pathol. 1986;17:765-777.

• 摘要

22.  Dalakas MC, Pezeshkpour GH, Gravell M, et al. Polymyositis associated with AIDS retrovirus. JAMA. 1986;256:2381-2383.

• 摘要

23.  Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007;61:466-475.

• 摘要

24.  Christopher-Stine L, Plotz PH. Myositis: an update on pathogenesis. Curr Opin Rheumatol. 2004;16:700-706.

• 摘要

25.  Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48:2285-2293.

• 全文
• 摘要

26.  Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59:872-880.

• 摘要

27.  Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297-301.

• 全文
• 摘要

28.  Banker BQ. Dermatomyostis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol. 1975;34:46-75.

• 摘要

29.  Carpenter S, Karpati G, Rothman S, et al. The childhood type of dermatomyositis. Neurology. 1976;26:952-962.

• 摘要

30.  Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.

• 摘要

31.  Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487-1498.

• 摘要

32.  Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65-71.

• 摘要

33.  Lindvall B, Dahlbom K, Henriksson KG, et al. The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand. 2003;107:134-141.

• 摘要

34.  Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008-2019.

• 摘要

35.  Greenberg SA. Inflammatory myopathies: disease mechanisms. Curr Opin Neurol. 2009;22:516-523.

• 摘要

36.  Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010;12:198-203.

• 摘要

37.  Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:1257-1266.

• 摘要

38.  Rider LG, Shamim E, Okada S, et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum. 1999;42:1285-1290.

• 全文
• 摘要

39.  Lampe JB, Gossrau G, Kempe A, et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol. 2003;250:1313-1317.

• 摘要

40.  Pachman LM, Fedczyna TO, Lechman TS, et al. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep. 2001;3:379-386. [Published correction appears in Curr Rheumatol Rep. 2001;3:preceding table of contents.]

• 摘要

41.  Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:891-916.

• 摘要

42.  Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol. 2004;18:331-344.

• 摘要

43.  Dorph C, Lundberg IE. Idiopathic inflammatory myopathies - myositis. Best Pract Res Clin Rheumatol. 2002;16:817-832.

• 摘要

44.  Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112:727-747.

• 摘要

45.  Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000;55:1385-1387.

• 摘要

46.  Lyon MG, Bloch DA, Hollak B, et al. Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey. J Rheumatol. 1989;16:1218-1224.

• 摘要

47.  Albert JM, Ott HJ. Calcifying dermatomyositis following antitentanus vaccination. Arch Int Med. 1983;143:1457-1458.

• 摘要

48.  Kass E, Straume S, Mellbye OJ, et al. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol. 1979;8:187-191.

• 摘要

49.  Ehrengut W. Dermatomyositis and vaccination. Lancet. 1978;1:1040-1041.

• 摘要

50.  Dion E, Chérin P. Use of muscular MRI in inflammatory myopathies [in French]. Rev Med Interne. 2004;25:435-441.

• 摘要

51.  Mittal GA, Wadhwani R, Shroff M, et al. Ultrasonography in the diagnosis and follow-up of idiopathic inflammatory myopathies - a preliminary study. J Assoc Physicians India. 2003;51:252-256.

• 摘要

52.  Backhaus M, Schmidt WA, Mellerowicz H, et al. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 6: ultrasonography of the wrist/hand [in German]. Z Rheumatol. 2002;61:674-687.

• 摘要

53.  Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252:1448-1454.

• 摘要

54.  Fan X, Rouleau GA. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy. Can J Neurol Sci. 2003;30:8-14.

• 摘要

55.  Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003;16:569-575.

• 摘要

56.  Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001;24:1562-1566.

• 摘要

57.  Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379-387.

• 摘要

58.  Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40:581-586.

• 摘要

59.  Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985;12:1140-1148.

• 摘要

60.  Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2013;(6):CD004760.

• 全文
• 摘要

61.  Chérin P, Herson S, Wechsler B, et al. Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis: an open trial in 15 patients [in French]. Presse Med. 1991;20:244-249.

• 摘要

62.  Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2 suppl 1):S57-S107.

• 摘要

63.  Pul R, Stangel M. Using immunoglobulins in muscular disease treatment. Expert Opin Biol Ther. 2008;8:1143-1150.

• 摘要

64.  Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5:548-557.

• 摘要

65.  Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24:457-462

• 摘要

66.  Mastaglia FL, Garlepp MJ, Phillips BA, et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 2003;27:407-425.

• 摘要

67.  Chérin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91:162-168.

• 摘要

68.  Chérin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467-474.

• 摘要

69.  Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19:138-141.

• 摘要

70.  Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol. 1991;9:658-659.

• 摘要

71.  Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol. 1979;115:1251-1252.

• 摘要

72.  Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome. Arthritis Rheum. 1990;33:1579-1581.

• 摘要

73.  Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-137.

• 摘要

74.  Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36:319-324.

• 摘要

75.  Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J. 2006;82:417-424.

• 摘要

76.  Correia O, Polonia J, Nunes JP, et al. Severe acute form of adult dermatomyositis treated with cyclosporine. Int J Dermatol. 1992;31:517-519.

• 摘要

77.  Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1:1063-1066.

• 摘要

78.  Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855-2859.

• 摘要

79.  Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37-41.

• 全文
• 摘要

80.  Schneider C, Gold R, Schafers M, et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve. 2002;25:286-288.

• 摘要

81.  Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762-1763.

• 摘要

82.  Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27:1542-1545.

• 摘要

83.  Waite LE, Madhok R. Tacrolimus - a potential therapy for polymyositis? Rheumatology (Oxford). 2009;48:858-859.

• 全文
• 摘要

84.  Shimojima Y, Gono T, Yamamoto K, et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol. 2004;23:262-265.

• 摘要

85.  Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006;34:284-291.

• 摘要

86.  Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65-69.

• 全文
• 摘要

87.  Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006;8:167-173.

• 摘要

88.  Dau PC, Bennington JL. Plasmapheresis in childhood dermatomyositis. J Pediatr. 1981;98:237-240.

• 摘要

89.  Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380-1384.

• 摘要

90.  Hubbard WN, Walport MJ, Halnan KE, et al. Remission from polymyositis after total body irradiation. Br Med J (Clin Res Ed). 1982;284:1915-1916.

• 全文
• 摘要

91.  Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve. 1988;11:120-123.

• 摘要

92.  Cherin P, Herson S, Coutellier A, et al. Failure of total body irradiation in polymyositis: report of three cases. Br J Rheumatol. 1992;31:282-283.

• 摘要

93.  Kelly JJ Jr, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology. 1986;36:1264-1266.

• 摘要

94.  Cumming WJ. Thymectomy in refractory dermatomyositis. Muscle Nerve. 1989;12:424.

• 摘要

95.  Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88:83-105.

• 摘要

96.  Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010;62:219-225.

• 全文
• 摘要

97.  Ruperto N, Pistorio A, Oliveira S, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671-678.

• 摘要

98.  Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324.

• 摘要

99.  Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003;50:10-15.

• 摘要

100.  Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-607.

• 全文
• 摘要

101.  Lindberg C, Trysberg E, Tarkowski A, et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61:260-262.

• 摘要

102.  Oddis CV. Idiopathic inflammatory myopathy: management and prognosis. Rheum Dis Clin North Am. 2002;28:979-1001.

• 摘要

103.  Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22-26.

• 全文
• 摘要

104.  Torres C, Belmonte R, Carmona L, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity. 2006;39:205-215.

• 摘要

105.  Medsger TA Jr, Robinson H, Masi AT. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum. 1971;14:249-258.

• 摘要

106.  Maugar YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263-274.

• 摘要

107.  Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999;78:139-147.

• 摘要

108.  Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237.

• 摘要

109.  Danko K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35-42.

• 摘要

110.  Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 1992;35:1211-1217.

• 摘要

111.  Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006;39:161-170.

• 摘要

112.  de Merieux P, Verity MA, Clements PJ, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum. 1983;26:961-968.

• 摘要

113.  Kagen LJ, Hochman RB, Strong EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630-636.

• 摘要